FindMyKOL
Clinical trialNCT05661409CompletedPhase 4Interventional

Sugammadex as Rescue Therapy

NCT05661409 is a phase 4 interventional trial sponsored by Emory University. As of 18 Nov 2026, it is completed. It studies Placebo and Sugammadex in Neuromuscular Blockade. The registry lists an enrollment of 46 participants at 1 site in 1 country. The registry lists a start date of 21 Jul 2023 and a primary completion date of 2 Aug 2024.

SponsorEmory University →Enrollment46Neuromuscular Blockade
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT05661409
FieldValue
Registry IDNCT05661409
StatusCompleted
PhasePhase 4
Study typeInterventional trial
Lead sponsorEmory University
Enrollment46
Registered sites1
Countries1
ConditionsNeuromuscular Blockade
DrugsPlacebo and Sugammadex
Start21 Jul 2023
Primary completion2 Aug 2024
Study completion2 Aug 2024
Last update posted5 Sept 2025

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Neuromuscular blocking agents (NMBAs) are commonly used in the practice of anesthesiology for skeletal muscle relaxation to facilitate tracheal intubation, mechanical ventilation, and to provide optimal surgical conditions. In order to prevent residual NMB, it is vital to adequately reverse any use of a non-depolarizing NMBA. This was historically done using an anticholinesterase such as neostigmine, which would increase the concentration of acetylcholine at the neuromuscular junction leading to the return of neuromuscular transmission. Unfortunately, there are disadvantages to the use of an anticholinesterase. It was in this context that sugammadex was found to be a valuable addition to the anesthesiologist's armamentarium. It is a modified γ-cyclodextrin that encapsulates the aminosteroid NMBAs rocuronium and vecuronium. This project is a double-blind randomized placebo-controlled dose-response trial that aims to determine the time taken to achieve adequate reversal comparing five doses of sugammadex as rescue therapy following inadequate reversal with neostigmine. The study team will recruit patients aged 18 years and above from the main operating room and outpatient surgery center at Grady Memorial Hospital who are undergoing elective surgery under general anesthesia, who has received NMB, received neostigmine for NMB reversal, and achieved a TOF count ≥ 3 twitches but not a TOF ratio of 0.9 fifteen minutes after neostigmine was given. Those with a TOF count \< 3 twitches will drop out of the study as there are already specified doses of sugammadex for that level of NMB

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Georgia, United States1 site
  • Grady Memorial Hospital

    Atlanta

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgia: 1 siteGA1HawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

PlaceboSugammadex
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT05661409

Each answer restates registry values shown on this page.

What is NCT05661409?

NCT05661409 is a phase 4 interventional trial sponsored by Emory University. It studies Placebo and Sugammadex in Neuromuscular Blockade.

Who leads NCT05661409?

The registry names Matthew Whalin, MD (principal investigator, Assistant Professor) as the overall official.

Where does NCT05661409 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT05661409 study?

The registered drug and biological interventions are Placebo and Sugammadex.

When did NCT05661409 end?

The registry lists a primary completion date of 2 Aug 2024 and a study completion date of 2 Aug 2024. The sponsor last updated the record on 5 Sept 2025.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.